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ENPP1 is well known for its role in regulating skeletal and soft tissue mineralization. It primarily exerts its function through the generation of pyrophosphate, a key inhibitor of hydroxyapatite formation. A number of previous studies have suggested that ENPP1 also contributes to a range of human diseases including diabetes, cancer, cardiovascular disease and osteoarthritis. In this review, we summarize the pathological roles of ENPP1 in mineralization and these soft tissue disorders. We also discuss the underlying mechanisms through which ENPP1 exerts its pathological effects. A fuller understanding of the pathways through which ENPP1 acts may help to develop novel therapeutic strategies for these commonly diagnosed morbidities. 



















Bone as an Endocrine Organ 
The bones of the skeleton exert many functions including supporting and protecting internal organs, contributing to hematopoiesis and maintaining mineral homeostasis. Throughout life, bone is constantly remodeled. Bone remodeling is a highly conserved and regulated process that controls bone homeostasis and maintains skeletal structural integrity. This vital function is characterized by alternating phases of bone resorption and bone formation which results in the human skeleton replacing itself every 10 years [1]. Recently, bone has been suggested to also act as an endocrine organ critical for the regulation of systemic metabolism [2]. This is supported following the discovery of osteocalcin, a non-collagenous protein, which is specifically secreted by osteoblasts and is capable of acting at distal sites to elicit systemic effects [3]. Osteocalcin, also known as bone gamma-carboxyglutamic acid-containing protein, in it’s under or un-carboxylated forms is known to have hormonal functions.  Via its endocrine function, osteocalcin acts systemically to enhance pancreatic β-cell proliferation, insulin secretion, peripheral insulin sensitivity and energy expenditure [4, 5]. 

Ectonucleotide pyrophosphatase/phosphodiesterase1 (ENPP1) is an established regulator of skeletal and soft tissue mineralization (see Glossary) and is also involved in bone remodeling [6, 7]. We have previously reported that Enpp1-/- mice are protected against obesity and diabetes, through alterations to their osteocalcin carboxylation status [8]. These data support the growing notion that bone is a key endocrine regulator of metabolism and energy balance via osteocalcin, as well as new and emerging alternative mechanisms [8-10]. Together, this indicates that bone remodeling regulators play an important role in energy metabolism. Additionally, studies reported in recent years have demonstrated many other pathological effects of ENPP1 in a variety of human diseases including – but not limited to – diabetes [11], cancer [12], cardiovascular disease [13] and osteoarthritis [14]. In this review, we summarize the underlying mechanisms through which ENPP1 regulates the mineralization process and physiological functions. We will also discuss the underlying mechanisms whereby ENPP1 exerts its pathological effects. 

Pathological role of ENPP1 in bone and soft tissue mineralization 
The ratio of mineralization promoters and inhibitors is critical for permitting and restricting, respectively, mineralization in skeletal tissue [15]. This mineralization process occurs by a number of physiochemical and biochemical processes, which allow the formation and deposition of hydroxyapatite (HA) into the extracellular matrix. Pyrophosphate (PPi) is one of the most important inhibitors of HA deposition. There are three primary regulators of PPi: ENPP1, tissue non-specific alkaline phosphatase (TNAP) and PPi-channeling protein ANK. ENPP1 hydrolyzes ATP to generate PPi, which inhibits HA crystal formation and deposition, serving to inhibit mineralization [18] (Box 1). Conversely, TNAP’s main function is to hydrolyze PPi to inorganic phosphate to lower the levels of this mineralization inhibitor and while doing so it generates phosphate for HA formation [21]. ANK is a transmembrane protein that directly transports intracellular PPi to the extracellular matrix, where it functions as a key inhibitor of mineralization [22]. In addition to these three proteins, the ATP-binding cassette subfamily C member 6 (ABCC6) is another key regulator of PPi formation and matrix mineralization. Inactivating mutations of ABCC6 result in pseudoxanthoma elasticum (PXE), an autosomal recessive disease characterized by progressive ectopic mineralization of the matrix in skin, eyes, and arteries [23-25]. Similar phenotypes of human PXE pathology were observed in Abcc6 deficient mice [26, 27]. Interestingly, ectopic mineralization seen in Abcc6 deficient mice was significantly reduced by circulating PPi [28, 29]. Further studies disclosed that hepatic ABCC6 mediated the release of ATP, which was hydrolyzed to PPi by ENPP1 within the liver vasculature [30]. Consistent with this, patients with PXE or Abcc6 deficient mice exhibited significantly reduced plasma PPi levels [29, 30]. These studies suggest that ABCC6-mediated ATP secretion by the liver is the primary source of circulating PPi. These four proteins are critical for providing the correct PPi/Pi ratio permissive for physiological mineralization, and together they are part of a critical wider network of mineralization regulators. 
ENPP1 is highly expressed in a range of tissues, including bone, cartilage and adipose tissue [31, 32], with moderate expression levels in the heart, liver, placenta and the testes [33, 34]. ENPP1 primarily exerts its function in bone, where it generates PPi to inhibit HA precipitation and prevents pathophysiological over-mineralization [35]. The functional roles of ENPP1 in regulation of mineralization is well demonstrated in a number of established mouse models. This is supported by phenotypic observations of the ‘tiptoe’ walking mouse model (ttw/ttw), used initially to demonstrate a link between defective Enpp1 expression and altered bone mineralization [36]. The ttw/ttw mouse model has a naturally occurring stop codon in the ENPP1 coding sequence, resultant of a homozygous G1813T mutation. These animals exhibit spontaneous mineralization of the articular cartilage, increased vertebral cortical bone formation and pathological joint hyperostosis [37]. Transgenic mice with a homozygous disruption in exon 9 of the Enpp1 gene phenocopy the ttw/ttw mouse model [38]. A comparable phenotype is observed in mice carrying a p.V246D missense mutation in the Enpp1 gene, known as asj/asj mice [39]. In addition, the spontaneous Enpp1 asj-2J mutant mouse with a large deletion/insertion mutation in the Enpp1 gene showed phenotypes with similarity to that of asj/asj mice [40]. These murine Enpp1 genetic variants show an abnormally low level of PPi and are widely used as mouse models of generalized arterial calcification of infancy (GACI).

Rare autosomal recessive ENPP1 mutations in humans result in GACI. This disease is typically characterized by the presence of mineralization of both large and medium sized arteries, with arterial stenosis caused by intimal proliferation. The most severely affected individuals typically die within the first 6 months of post-natal life, as a result of end-organ damage, including myocardial infarction [41]. Approximately 70% of GACI cases are attributable to mutations in ENPP1, with more than 40 causative variations delineated [42]. Some of these mutations have been functionally characterized in vitro, whereby a complete loss or partial reduction of, ENPP1 enzymatic activity is reported [43, 44] (Table 1 and Figure 1).  

The treatment of GACI to date largely revolves around the use of bisphosphonates – which are analogues of PPi, and act via inhibiting osteoclastic bone resorption [45]. In the Enpp1asj mutant mouse, a mouse model of GACI, the use of bisphosphonates replenishes the abnormally low levels of PPi [45]. Bisphosphonates show a degree of efficacy in preventing arterial mineralization, however patients are likely to suffer from dysregulated bone resorption, likely due to the inhibitory effects of bisphosphonates on osteoclasts [46, 47]. A recent study indicated that the oral administration of bisphosphonates represents a valid and practical route for the treatment of PXE and GACI [48]. Work by this group also revealed that the provision of PPi-supplemented drinking water was effective in attenuating the ectopic mineralization phenotype characteristically associated with mouse models of PXE and GACI [48]. Encouragingly, a recent clinical trial showed that etidronate, a stable PPi analog, reduced arterial calcification and subretinal neovascularization events in patients with PXE, without important safety issues [49]. These studies indicate that PPi analogs such as bisphosphonates and etidronate may represent a cost-effective and practical treatment method for GACI and PXE. Interestingly, one group have recently demonstrated that a daily, subcutaneous dose of the extracellular ENPP1 domain fused to the Fc region of human IgG1 eliminates the arterial mineralization, mortality and other potentially fatal sequelae of GACI in an established mouse model of GACI (Enpp1asj mice) [50]. This clinical response can be explained by a normalization of the serum and tissue PPi concentrations in the Enpp1asj mice. These investigations provide strong support for the integral role of ENPP1 in the regulation of the Pi/PPi ratio and tissue mineralization. 

ENPP1 may also act as an anti-aging factor through altering Klotho expression and vitamin D metabolism. Klotho is a well characterized anti-aging factor that regulates phosphate homeostasis [51]. Klotho deficient mice display similar phenotypes to that of human premature aging, including short lifespan, arteriosclerosis and ectopic calcification in soft tissue [52]. A recent study demonstrated that Enpp1 ttw/ttw mice under high phosphate conditions exhibited premature aging phenotypes, resembling human aging and Klotho deficient mice [53]. Interestingly, significantly down-regulated Klotho expression in kidney and elevated serum vitamin D levels were observed in Enpp1 ttw/ttw mice fed with high phosphate diet. Moreover, the premature aging phenotypes observed in Enpp1 ttw/ttw mice under phosphate overload conditions were completely rescued by ablation of the vitamin D receptor [53]. 

Emerging role of ENPP1 in non-skeletal diseases
Whilst it has long been acknowledged that ENPP1 acts as a mineralization regulator, its function in non-skeletal disease has now also been well established. A role for ENPP1 in the pathogenesis of insulin resistance, type 2 diabetes (T2D), cardiovascular disease, cancer metastasis and osteoarthritis have now been established. In the following sections, we outline our current understanding of ENPP1 in these human diseases and discuss the underlying mechanisms through which ENPP1 exerts its pathological effects. 

ENPP1, Insulin resistance and Type 2 diabetes 
The global incidence of diabetes is predicted to reach 642 million adults by the year 2040 [54], with incidence becoming increasingly rapid and widespread throughout developed and developing countries. T2D is currently the most common metabolic disorder worldwide, with rapidly growing population of pre-diabetic individuals (79 million estimated individuals in the US alone). As such, T2D represents an ever increasing burden of disease, morbidity, mortality and cost to the individual and society at large [55]. 

Insulin resistance is pathogenic for T2D. The link between ENPP1 and insulin signaling was identified more than 20 years ago when one study reported that ENPP1 expression was increased in the muscle cells from insulin-resistant human patients. Insulin in these cells was unable to promote auto-phosphorylation of the insulin receptor (IR), raising the possibility that ENPP1 could be an inhibitor of the IR [56]. Since then, a large body of evidence has emerged to support the important role of ENPP1 in insulin signaling. The overexpression of Enpp1 in cultured human mammary epithelial cells (MCF7) resulted in a decrease of insulin responsiveness and insulin resistance in patients was associated with elevated ENPP1 expression in a variety of tissue types (e.g. muscle, fat, fibroblasts) [57, 58]. Further studies have shown that ENPP1 inhibits IR function by directly interacting with the receptor α-subunit, thereby preventing receptor β-subunit auto-phosphorylation and its downstream signaling [59, 60] (Figure 2). Animal studies have demonstrated that overexpression of ENPP1 in muscle, liver or adipose tissue induces insulin resistance and glucose intolerance in rodents [61-63]. Furthermore, Enpp1-/- mice demonstrate a moderately improved glucose homeostasis on regular chow diet. However, when challenged with chronic high-fat diet feeding, these mice demonstrate a pronounced resistance to both obesity and diabetes [8]. This could be explained by the increased levels of the insulin-sensitizing hormone osteocalcin observed in these mice. Osteocalcin is produced by bone-forming osteoblasts and its partially or fully under-carboxylated bioactive form acts at distal sites to promote insulin secretion by pancreatic -cells and to increase insulin sensitivity in target tissues [3]. These observations support the concept that ENPP1 functions via bone to regulate energy metabolism through osteocalcin secretion. This may be a key regulatory mechanisms for global energy metabolism and the T2D dysregulation of glucose metabolism.

ENPP1 may also contribute to T2D through its actions in the liver. A recent study revealed that suppressed ENPP1 expression results in improved insulin sensitivity in HepG2 liver-, L6 skeletal muscle- and INS1E beta-cells in vitro [64]. In addition, improved insulin sensitivity is observed following the adenovirus mediated liver-specific knockdown of Enpp1 expression in the db/db mouse model of diabetes. These liver-specific Enpp1 deficient mice exhibited an 80% decrease in Enpp1 gene expression and a 25% lower fasting plasma glucose [65]. Conversely, mice with adenovirus-mediated overexpression of human ENPP1 in liver exhibited higher glucose and insulin levels, and abnormal glucose tolerance. Moreover, these mice had reduced IR function and signaling, and elevated key gluconeogenic enzymes in their livers [61]. Further studies are required to fully elucidate the complex regulatory hepatic mechanisms of ENPP1’s action, PPi production and regulation of T2D. 

Multiple human genetic studies, including genome wide sequence analysis (GWAS), have mapped the ENPP1 chromosome locus to insulin resistance, hypertriglyceridemia, childhood and adult obesity and increased risk of T2D. The ENPP1 polymorphism K121Q is the most widely studied. It has been reported that this polymorphism is associated with T2D [66, 67] and coronary artery disease [66, 68]. Functional studies have shown that the Q121 variant shows increased IR inhibition activity in skeletal muscle- and liver-cells [64]. Recently, several studies have also reported that the Q121 variant is associated with bone disorders [69], kidney function [70] and cardiovascular events [71-73] in patients with diabetes. However, conflicting results exist. Two previous studies found no association of Q121 with T2D in the Iranian [74] and northern Chinese populations [75], while previous studies on a Finnish population showed a strong linkage to early onset T2D [76]. These data suggest that ethnic origin and environmental factors may contribute to the influence of the Q121 variant in the development of T2D.

The inhibitory effect of ENPP1 on insulin signaling may also contribute to Cole disease. Cole disease is a rare autosomal-dominant disorder with coexistence of abnormal keratinization and aberrant pigmentation in the skin, while cutaneous calcification is uncommon [77]. Previous studies have reported the association of ENPP1 mutations with Cole disease [78, 79]. Interestingly, some family members of Cole disease patients carrying the ENPP1 mutation present with no clinical features of Cole disease [79]. This suggests that ENPP1 mutations are not always sufficient for the manifestation of Cole disease. A recent study indicated that a novel homozygous ENPP1 mutation c.358T>C (p.Cys120Arg) was associated with an autosomal-recessive and more extensive form of Cole disease [80]. The ENPP1 mutation resulted in the decreased expression of ENPP1 in melanocytes derived from patients [80]. Further analysis showed that the p.Cys120Arg responsible for recessive Cole disease retained partial ENPP1 dimer formation, while the p.Cys164Ser mutation responsible for dominant Cole disease severely affected dimerization [80]. RNA-seq analysis of patient-derived melanocytes revealed that melanocyte development and pigmentation signaling pathways were significantly altered [80]. All currently reported ENPP1 mutations associated with Cole disease lie within the somatomedin-B-like (SMB) domain (Figure 1). Interestingly, previous studies have reported that the SMB domain of ENPP1 interacts with IR and inhibits insulin signaling [81]. Future investigations are warranted to understand the interplay between ENPP1 and insulin signaling in the pathogenesis of Cole disease. 

ENPP1 in Cardiovascular Disease
Cardiovascular disease represents the leading cause of death and disability throughout the world. In 2015 alone, 17.7 million people died from cardiovascular disease, which amounts to 31% of the total global deaths for that year (https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)) (​https:​/​​/​www.who.int​/​news-room​/​fact-sheets​/​detail​/​cardiovascular-diseases-(cvds))​). Of these deaths, approximately 7.4 million were caused by coronary heart disease, whereas 6.7 million were due to stroke. A major risk factor for the incidence of either stroke or heart diseases is atherosclerosis. A build-up of fatty material lining the arterial walls is characteristic of atherosclerosis which results in a narrowing of the artery diameter resulting in a restricted and/or blocked blood flow [82]. Vascular calcification is a hallmark of atherosclerosis [83]. ENPP1 expression has been reported to be decreased in calcified plaques compared to un-calcified atherosclerotic lesions in human carotid endarterectomy samples [84]. This suggests that atherosclerotic lesion progression is attenuated and mineralization in the atherosclerotic plaque is enhanced due to a total or partial deficiency of ENPP1. Indeed, partial and severe Enpp1 deficiency in mice (heterozygous and homozygous ttw phenotype) attenuates atherosclerotic lesion progression, potentially mediated by secreted phosphoprotein 1 (Spp1) expression. It is observed that there is decreased Spp1 expression in the vascular smooth muscle cells of Enpp1 deficient mice, including ttw/ttw ApoE-/- mouse strains [34]. Such findings suggest that Enpp1 is involved in the promotion of atherosclerosis, and that this process is to some degree co-regulated by Spp1.

Sickle cell anaemia is associated with thrombotic stroke in 5-10% of pediatric patients and represents a serious sequelae of sickle cell disease [85]. Stroke protection in children with sickle cell anaemia has been associated with the K173Q mutation of ENPP1 which was identified through whole-genome sequencing [85]. Interestingly, the ENPP1 K173Q mutation was previously shown to be associated with increased serum levels of soluble ENPP1 protein in children [86]. Therefore, this mutation may increase PPi concentration in serum, which likely results in a protective mechanism whereby PPi inhibits vascular calcification and leads to reduction in stroke incidence.

ENPP1 and Cancer
ENPP1 is well recognized for its roles in purinergic signaling, which is inextricably linked with cancer incidence [87, 88]. Extracellular nucleosides and nucleotides are critical signaling molecules in the majority of cell types, either by stimulating P1 (adenosine) or P2 (nucleotide) receptors [89]. In addition, ENPP1 expression has been reported to be elevated in a number of cancer-simulating conditions, such as in the membranes of rat C6 glioma cells [90], human astrocytic brain tumors [91] and human glioblastoma stem-like cells [92]. A correlation between the degree of increased ENPP1 expression and aggressiveness of astrocytic brain tumors has also been observed [91]. The targeted application of ENPP1 inhibitors may offer a novel therapeutic route for the treatment of certain brain cancers.  

Bone is the most common site for breast cancer to metastasis, with 70% of metastatic breast cancer sufferers experiencing bone pain, fracture, and hypercalcaemia [93, 94]. ENPP1 expression was found to be increased in human breast cancer cell lines known to cause bone metastasis in animal models compared with non-metastatic and normal mammary epithelial cell lines [95]. In addition, stable overexpression of ENPP1 in the breast cancer cell line MDA-MB-231 enhanced their ability to form tumors in the bone [95]. The elevated expression levels of ENPP1 in the tumor cells is likely to lead to an increase in PPi production and reduced matrix mineralization in the bone, potentially altering the bone formation/bone resorption ratio and creating an environment which may facilitate the development of a bone lesion. Tumor cell invasion may be further fuelled by the liberation of growth factors from the resorbed bone. 

ENPP1 and Osteoarthritis
Osteoarthritis (OA) is one of the leading causes of disability, representing the most common joint disorder in the UK, with an estimated 10-15% of individuals aged over 60 years experiencing a degree of OA. With an ever-increasing ageing population and a confounding obesity epidemic, the global incidence of symptomatic OA is only set to increase further. Over the past decade, a number of candidate genes have been implicated by genome-wide association studies in the pathology of OA, including ENPP1, whereby polymorphisms have been associated with hand OA in a Chuvasha population [96]. This association with OA pathogenesis is consistent with ENPP1’s expression within the joint where it is expressed by both chondrocytes and osteoblasts [97, 98]. The liberation of phosphate from PPi may contribute to OA onset and progression. Whilst mouse models have confirmed this likely mechanism they have also identified possible alternative pathways in OA pathogenesis. Enpp1-/- mice present with ectopic mineralization of articular cartilage, joint capsule and tendons and exhibit OA-like changes [98, 99-101]. Also, pro-inflammatory cytokines, a result of OA induced inflammation - can downregulate Enpp1 expression in cartilage, thereby inhibiting PPi generation, which consequently leads to ossification and triggers osteoarthritic changes in mice [98]. Further studies have reported that ENPP1 inhibits ectopic joint mineralization and maintains articular chondrocytes by repressing hedgehog signaling [101]. Continued investigation is required to determine the specific role of ENPP1 in cartilage homeostasis and OA potential therapeutic applications by using conditional Enpp1 knockout mice in chondrocytes.

Concluding Remarks and Future Perspectives
ENPP1 is critical for the regulation of calcium/phosphate and PPi homeostasis, skeletal and soft tissue mineralization, and the maintenance of skeletal structural integrity and function. As adipose tissue, heart, liver, placenta and the testes all express ENPP1 the physiological importance of ENPP1 to metabolic pathways other than mineralization, is of great interest (see Outstanding Questions). Indeed, a number of studies have reported that ENPP1 is associated with a wide range of human disease such as T2D, cardiovascular disease, cancer and OA (Figure 3). These findings suggest that the mechanisms in which ENPP1 are involved throughout various tissues and organ types are much more complex and varied than initially anticipated. 

The insulin-sensitized phenotype observed in global Enpp1 deficient mouse may be a consequence of ENPP1 ablation in insulin-sensitive tissues such as liver, adipose and skeletal muscle. Tissue-specific ablation of ENPP1 is therefore required in future work to delineate the individual tissue(s)/cell type(s) driving the metabolic phenotype of the Enpp1−/− mouse. Furthermore, metabolic OA has now been characterized as a subtype of OA, which has strong associations and shared mechanisms with other metabolic syndrome components [102].  

Lastly, although it has been reported that ENPP1 facilitates breast cancer bone metastasis, its precise mechanisms remains largely unknown. The presence of tumor cells expressing ENPP1 may elevate the levels of PPi, which subsequently inhibits bone mineralization and creates a favorable environment for bone resorption. Increased bone resorption is critical to the development of bone metastasis as it liberates growth factors from the bone, accelerating tumor growth [103]. In addition, the involvement of ENPP1 in insulin and purinergic signaling may also participate in the crosstalk between tumor cells and the bone environment. 

This review has presented a body of evidence supporting the pathological roles of ENPP1 in bone and soft tissue mineralization, as well as T2D, cardiovascular disease, cancer and OA. This review has also discussed the current knowledge pertaining to the underlying mechanisms through which ENPP1 contributes to these morbidities. A greater understanding of the actions of ENPP1 in these diseases, in concurrence with the full elucidation of the mechanisms underpinning and connecting the known effects of ENPP1, may stimulate the development of novel therapeutic treatments for patients with bone diseases, cardiovascular pathologies and T2D.

Acknowledgements



















Endarterectomy: refers to a surgical procedure to remove the atheromatous plaque from the arterial wall.

Hypertriglyceridemia: refers to high blood levels of triglycerides, an ester derived from glycerol and three fatty acids.

Hypercalcaemia: refers to high calcium concentration in blood.

Hedgehog Signaling: refers to an intricate signal transduction pathway that governs the proper cell differentiation.  

Metastasis: refers to cancer spreads from its original place to other location in the body.

Pseudoxanthoma elasticum: a genetic disease that causes fragmentation and mineralization of elastic fibers in tissues. In humans, PXE is mainly resulted from autosomal recessive mutations in the ABCC6 gene.

Purinergic Signaling: refers to a form of extracellular signaling exerted by purine nucleotides and nucleosides such as adenosine and ATP. Purinergic signaling regulates cellular functions through the activation of purinergic receptors in the cells.

Skeletal mineralization: a process by which hydroxyapatite (a crystalline complex of calcium and phosphate) precipitates in the extracellular matrix. 

Type 2 diabetes (T2D): a long-term metabolic syndrome that is characterized by high blood sugar and insulin resistance. Two major pathophysiologic abnormalities of T2D include: (1) insufficient secretion of insulin from the β-cells of the pancreatic islets and (2) impaired insulin action in target tissues.
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Figure 1: Schematic Representation of Human ENPP1 Mutations and Their Associated Disease
To date, more than 40 ENPP1 mutations have been reported to be associated with generalized arterial calcification of infancy (GACI). The mutations that have been functionally characterized in vitro are marked on a schematic representation of ENPP1 (Red). The currently reported ENPP1 mutations associated with Cole disease (Purple) and hypophosphatemic rickets (Blue) are also presented. Most of the reported ENPP1 mutations associated with GACI or hypophosphatemic rickets are located in the phosphodiesterase or nuclease-like domain, while ENPP1 mutations associated with Cole disease lie in the SMB domain.


Figure 2: Schematics of Insulin Receptor Binding in the Absence and Presence of ENPP1 
In the absence of ENPP1, insulin binds to the α-subunits of the insulin receptor (IR) and stimulates a cascade of events. Notably, this binding facilitates tyrosine kinase mediated auto-phosphorylation of the IR β-subunits, leading to the downstream mediation of glucose regulation by the subsequent activation of pathways (e.g. P13K and AKT activation) resulting in altered gene expression and/or growth. Insulin binding also stimulates the translocation of the GLUT4 receptor to the plasma membrane whereby it regulates intracellular glucose transport to muscle and adipose tissues and which leads to pleiotropic effects such as use of glucose, formation of glycogen, promotion of lipid synthesis and protein synthesis. When ENPP1 is present, it binds to the α-subunit of the IR. This results in a conformation change of the β-subunit, preventing tyrosine kinase binding and thus inhibiting insulin receptor β-subunit auto-phosphorylation. As such, the downstream mediation of glucose is disturbed. There is an absence of GLUT4 translocation to the plasma membrane, and dysregulation of glucose homeostasis resulting in insulin resistance. 
Figure 3: ENPP1 and Related Pathogenicity in Various Tissues. 









Table.1 Functional characterization of  ENPP1 mutations in GACI patients in vitro
No.	
Nucleotide change  	Amino Acid 
change 	Amino acid location 
in ENPP1 
functional domain	Enzyme activity	Cellular location	Extracellular 
PPi generation	Cells used for experiments	References
1	c.2,713–2,717delAAAGA	p.K905fsX920	Nuclease-like domain	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
2	c.2,677G>T	p.E893X	Nuclease-like domain	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
3	c.2,375A>G	p.N792S	Nuclease-like domain	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
4	c.2,320C>T	p.R774C	Nuclease-like domain	Moderately affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
5	c.2,176T>C	p.C726R	Nuclease-like domain	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
6	c.2,002G>A	p.E668K	Nuclease-like domain	Not significantly affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
7	c.1,831C>G	p.L611V	Not in functional domain	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
8	c.1,737G>C	p.L579F	Catalytic domain	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
9	c.1,441C>T	p.R481W	Catalytic domain	Moderately affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
10	c.1,367G>A	p.R456Q	Catalytic domain	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
11	c.936T>G	p.Y312X	Catalytic domain	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
13	c.376T>C	p.C126R	Somatomedin-B-like
domains	Severely affected	Not available	Not available	SaOS-2 ( osteosarcoma)	43
14	c.517A > C	p.K173Q	Somatomedin-B-like
domains	Moderately affected	Plasma membrane	Severely affected	HEK293 and COS7 (kidney cells)	44
15	c.583 T > C	p.C195R	Not in functional domain	No enzyme activity	Intracellular	No PPi generation	HEK293 and COS7 (kidney cells)	44
16	c.583 T > A	p.C195S	Not in functional domain	No enzyme activity	Intracellular	No PPi generation	HEK293 and COS7 (kidney cells)	44
17	c.902 A > G	p.Y301C 	Catalytic domain	No enzyme activity	Intracellular	No PPi generation	HEK293 and COS7 (kidney cells)	44
18	c.913 C > A	p.P305T	Catalytic domain	No enzyme activity	Plasma membrane	No PPi generation	HEK293 and COS7 (kidney cells)	44
19	c.1412A > G	p.Y471C	Catalytic domain	Severely affected	Plasma membrane	Severely affected	HEK293 and COS7 (kidney cells)	44
20	c.1510A > C	p.S504R	Catalytic domain	Severely affected	Plasma membrane	Severely affected	HEK293 and COS7 (kidney cells)	44
21	c.1538A > G	p.Y513C	Catalytic domain	No enzyme activity	Plasma membrane	No PPi generation	HEK293 and COS7 (kidney cells)	44
22	c.1612G > C	p.D538H	Catalytic domain	No enzyme activity	Plasma membrane	No PPi generation	HEK293 and COS7 (kidney cells)	44
23	c.1756G > A	p.G586R	Catalytic domain	No enzyme activity	Intracellular	No PPi generation	HEK293 and COS7 (kidney cells)	44
24	c.1976A > G	p.Y659C	Nuclease-like domain	Severely affected	Intracellular and 
plasma membrane	Severely affected	HEK293 and COS7 (kidney cells)	44
25	c.2002G > A	p.E668K	Nuclease-like domain	Not significantly affected	Plasma membrane	Moderately affected	HEK293 and COS7 (kidney cells)	44
26	c.2320C > T	p.R774C	Nuclease-like domain	Severely affected	Plasma membrane	Severely affected	HEK293 and COS7 (kidney cells)	44
27	c.2330A > G	p.H777R	Nuclease-like domain	Severely affected	Plasma membrane	Severely affected	HEK293 and COS7 (kidney cells)	44
28	c.2462 G > A	p.R821H	Nuclease-like domain	Moderately affected	Plasma membrane	Severely affected	HEK293 and COS7 (kidney cells)	44
29	c.2662C > T	p.R888W	Nuclease-like domain	No enzyme activity	Intracellular	No PPi generation	HEK293 and COS7 (kidney cells)	44


ENPP family members, comprising of seven structurally related isoenzymes (ENPP1-ENPP7), play a vital role in nucleotide catabolism. These enzymes are type II transmembrane metalloenzymes, characteristically containing a short intracellular domain, one transmembrane domain and an extracellular domain that comprises the conserved catalytic site  ADDIN EN.CITE  ADDIN EN.CITE.DATA [16]. The main subtype of the nucleotide hydrolyzing ENPP family is ENPP1, also known as plasma-cell antigen-1 (PC-1)  ADDIN EN.CITE  ADDIN EN.CITE.DATA [17]. The principal role of ENPP1 is to hydrolyze nucleotide triphosphates (principally ATP) to generate nucleoside monophosphates (e.g. AMP) alongside diphosphates (e.g. PPi)  ADDIN EN.CITE  ADDIN EN.CITE.DATA [18]. In addition to ATP, there are several other substrates for ENPP1, including dinucleotides (e.g. diadenosine polyphosphates) and nucleotide sugars with the release of nucleoside monophosphates [19]. Interestingly, the crystal structures of the extracellular region of mouse ENPP1 in complex with four different nucleotide monophosphates, have been previously reported and have shown that ENPP1 preferentially hydrolyzes ATP to produce AMP and PPi. Furthermore, ENPP1 was demonstrated to participate in different biological processes through distinct sets of domains: the catalytic and nuclease-like domains for skeletal mineralization and the somatomedin B (SMB)-like domains for insulin signaling [20].
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